Ming-Yu Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ming-Yu Lai has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Chun-Hui Wei
2 shared publicationsDan Jiang
1 shared publicationDun-Ke Jiang
1 shared publication- Guo-Du Tang
The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication - Hai-Xing Jiang
The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication Hui Chen
1 shared publication
Latest Publications
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 21 (36) , 4146
Screening differentially expressed serum proteins in gastric cancer by iTRAQ labeling coupled with 2D-LC-MS/MS
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 21 (36) , 4146
Screening differentially expressed serum proteins in gastric cancer by iTRAQ labeling coupled with 2D-LC-MS/MS
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 21 (14) , 1343
Indomethacin for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 21 (14) , 1343
Indomethacin for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis
- 9 June 2012
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 27 (12) , 1569-1578
Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways
Purpose Sphingosine kinase (SphK) 1 is an oncogenic enzyme promoting transformation, proliferation, and survival of a number of human tumor cells. However, its effect on colon cancer cell behavior has not been fully clarified. Methods SphK1 plasmid or SphK1 shRNA transfection and N,N-dimethylsphingosine (DMS) was used to regulate the expression and activity of SphK1 in colon cancer line LOVO. Cell proliferation, apoptosis, invasion, and protein expression were detected by MTT, flow cytometry, transwell chambers model, and western blot. The levels of metalloproteinases-2/9 (MMP-2/9) and urokinase plasminogen activator (uPA) were detected by ELISA. Results Overexpression of SphK1 after plasmid transfection markedly enhanced LOVO cell viability and invasiveness and reduced cell apoptosis. In contrast, inhibition of SphK1 by DMS and shRNA significantly suppressed cell viability and invasiveness but promoted cell apoptosis. SphK1 increased the constitutive expression of extracellular signal-regulated kinase1/2 (ERK1/2) but reduced the constitutive expression of p38 mitogen-activated protein kinase (MAPK). Blocking ERK1/2 pathway inhibited the biological effects induced by overexpression of SphK1. Blocking p38 MAPK pathway reversed the effects of DMS and SphK1 shRNA. Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580. Conclusions SphK1 enhances colon cancer cell proliferation and invasiveness, meanwhile suppressing cell apoptosis. SphK1 promoting the secretion of MMP-2/9 and uPA via activation of ERK1/2 and suppression of p38 MAPK pathways maybe the molecular mechanisms for its regulation of the malignant behavior of colon cancer cell.
- 9 June 2012
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 27 (12) , 1569-1578
Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways
Purpose Sphingosine kinase (SphK) 1 is an oncogenic enzyme promoting transformation, proliferation, and survival of a number of human tumor cells. However, its effect on colon cancer cell behavior has not been fully clarified. Methods SphK1 plasmid or SphK1 shRNA transfection and N,N-dimethylsphingosine (DMS) was used to regulate the expression and activity of SphK1 in colon cancer line LOVO. Cell proliferation, apoptosis, invasion, and protein expression were detected by MTT, flow cytometry, transwell chambers model, and western blot. The levels of metalloproteinases-2/9 (MMP-2/9) and urokinase plasminogen activator (uPA) were detected by ELISA. Results Overexpression of SphK1 after plasmid transfection markedly enhanced LOVO cell viability and invasiveness and reduced cell apoptosis. In contrast, inhibition of SphK1 by DMS and shRNA significantly suppressed cell viability and invasiveness but promoted cell apoptosis. SphK1 increased the constitutive expression of extracellular signal-regulated kinase1/2 (ERK1/2) but reduced the constitutive expression of p38 mitogen-activated protein kinase (MAPK). Blocking ERK1/2 pathway inhibited the biological effects induced by overexpression of SphK1. Blocking p38 MAPK pathway reversed the effects of DMS and SphK1 shRNA. Moreover, SphK1 was required for the production of MMP-2/9 and uPA in tumor cells, which was suppressed by ERK1/2 inhibitor U0126, but enhanced by the p38 MAPK inhibitor SB203580. Conclusions SphK1 enhances colon cancer cell proliferation and invasiveness, meanwhile suppressing cell apoptosis. SphK1 promoting the secretion of MMP-2/9 and uPA via activation of ERK1/2 and suppression of p38 MAPK pathways maybe the molecular mechanisms for its regulation of the malignant behavior of colon cancer cell.
- Open Access
- 1 January 2009
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 17 (9) , 931-934
Expression of trefoil factor 1 in gastric cancer and its correlation with neovascularization
目的: 观察三叶因子1(TFF1)和血管内皮生长因子(VEGF)在正常胃黏膜组织、癌旁组织和胃癌组织中的表达, 并探讨TFF1与胃癌发生发展过程中血管生成的关系. 方法: 采用SP免疫组化方法检测42例正常组织、66例癌旁组织和66例胃癌组织中TFF1和VEGF的表达, 以CD34标记血管内皮, 测定MVD. 结果: TFF1表达在正常胃黏膜组织→癌旁组织→胃癌组织中呈逐渐减弱趋势(209.40±16.00, 199.12±16.68, 189.17±16.20), 差异具有显著性(Pr = 0.811, P结论: TFF1作为一种胃癌特异性抑制因子, 在胃癌发生发展过程中并未促进新生血管的生成.
- 1 January 2009
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 17 (9) , 931-934
Open AccessExpression of trefoil factor 1 in gastric cancer and its correlation with neovascularization
目的: 观察三叶因子1(TFF1)和血管内皮生长因子(VEGF)在正常胃黏膜组织、癌旁组织和胃癌组织中的表达, 并探讨TFF1与胃癌发生发展过程中血管生成的关系. 方法: 采用SP免疫组化方法检测42例正常组织、66例癌旁组织和66例胃癌组织中TFF1和VEGF的表达, 以CD34标记血管内皮, 测定MVD. 结果: TFF1表达在正常胃黏膜组织→癌旁组织→胃癌组织中呈逐渐减弱趋势(209.40±16.00, 199.12±16.68, 189.17±16.20), 差异具有显著性(Pr = 0.811, P结论: TFF1作为一种胃癌特异性抑制因子, 在胃癌发生发展过程中并未促进新生血管的生成.